Pravachol | Pravastatin Sodium Tablet Breastfeeding
Nutrients from the food that you eat passes to your breast milk. Its good idea to take healthy diet while breastfeeding. You may need to consume more calories per day to support healthy body system. Some time it gets necessary take medicine while you are breastfeeding and as other food items passes into breast milk, medicine passes as well hence it becomes obvious to understand its effects while breastfeeding. We have analyzed many medications and in this sheet we will present some fact and known information associated with Pravachol | Pravastatin Sodium Tablet while breast-feeding.

What is Pravachol | Pravastatin Sodium Tablet used for?


Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. PRAVACHOL is an HMG-CoA reductase inhibitor (statin) indicated as an adjunctive therapy to diet to: Reduce the risk of MI, revascularization, and cardiovascular mortality in hypercholesterolemic patients without clinically evident CHD. (1.1) Reduce the risk of total mortality by reducing coronary death, MI, revascularization, stroke/TIA, and the progression of coronary atherosclerosis in patients with clinically evident CHD. (1.1) Reduce elevated Total-C, LDL-C, ApoB, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia. (1.2) Reduce elevated serum TG levels in patients with hypertriglyceridemia. (1.2) Treat patients with primary dysbetalipoproteinemia who are not responding to diet. (1.2) Treat children and adolescent patients ages 8 years and older with heterozygous familial hypercholesterolemia after failing an adequate trial of diet therapy. (1.2) Limitations of use: PRAVACHOL has not been studied in Fredrickson Types I and V dyslipidemias. (1.3) 1.1 Prevention of Cardiovascular Disease In hypercholesterolemic patients without clinically evident coronary heart disease (CHD), PRAVACHOL (pravastatin sodium) is indicated to: reduce the risk of myocardial infarction (MI). reduce the risk of undergoing myocardial revascularization procedures. reduce the risk of cardiovascular mortality with no increase in death from non-cardiovascular causes. In patients with clinically evident CHD, PRAVACHOL is indicated to: reduce the risk of total mortality by reducing coronary death. reduce the risk of MI. reduce the risk of undergoing myocardial revascularization procedures. reduce the risk of stroke and stroke/transient ischemic attack (TIA). slow the progression of coronary atherosclerosis. 1.2 Hyperlipidemia PRAVACHOL is indicated: as an adjunct to diet to reduce elevated total cholesterol (Total-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (ApoB), and triglyceride (TG) levels and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson Types IIa and IIb).1 as an adjunct to diet for the treatment of patients with elevated serum TG levels (Fredrickson Type IV). for the treatment of patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet. as an adjunct to diet and lifestyle modification for treatment of heterozygous familial hypercholesterolemia (HeFH) in children and adolescent patients ages 8 years and older if after an adequate trial of diet the following findings are present: LDL-C remains ≥190 mg/dL or LDL-C remains ≥160 mg/dL and: there is a positive family history of premature cardiovascular disease (CVD) or two or more other CVD risk factors are present in the patient. 1.3 Limitations of Use PRAVACHOL has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V).
1.1 Prevention of Cardiovascular Disease In hypercholesterolemic patients without clinically evident coronary heart disease (CHD), PRAVACHOL (pravastatin sodium) is indicated to: reduce the risk of myocardial infarction (MI). reduce the risk of undergoing myocardial revascularization procedures. reduce the risk of cardiovascular mortality with no increase in death from non-cardiovascular causes. In patients with clinically evident CHD, PRAVACHOL is indicated to: reduce the risk of total mortality by reducing coronary death. reduce the risk of MI. reduce the risk of undergoing myocardial revascularization procedures. reduce the risk of stroke and stroke/transient ischemic attack (TIA). slow the progression of coronary atherosclerosis.
1.2 Hyperlipidemia PRAVACHOL is indicated: as an adjunct to diet to reduce elevated total cholesterol (Total-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (ApoB), and triglyceride (TG) levels and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson Types IIa and IIb).1 as an adjunct to diet for the treatment of patients with elevated serum TG levels (Fredrickson Type IV). for the treatment of patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet. as an adjunct to diet and lifestyle modification for treatment of heterozygous familial hypercholesterolemia (HeFH) in children and adolescent patients ages 8 years and older if after an adequate trial of diet the following findings are present: LDL-C remains ≥190 mg/dL or LDL-C remains ≥160 mg/dL and: there is a positive family history of premature cardiovascular disease (CVD) or two or more other CVD risk factors are present in the patient.
1.3 Limitations of Use PRAVACHOL has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V).

What are the risk associated with Pravachol | Pravastatin Sodium Tablet usage while breastfeeding? What precautions shall I take while using it in breastfeeding?

Pravachol | Pravastatin Sodium Tablet high risk while breastfeeding
As Pravachol | Pravastatin Sodium Tablet is made of only Pravastatin sodium, and Pravastatin sodium is unsafe to use in breastfeeding we can safely reach on conclusion that Pravachol | Pravastatin Sodium Tablet is also unsafe to use while breastfeeding. Below is detailed analysis of Pravastatin sodium and Pravachol | Pravastatin Sodium Tablet during location. We recommend you to go through provided detailed analysis as below take decision accordingly. We also recommend you talk to your health care provider before making final decision.

Statement of Manufacturer/Labeler about breastfeeding usage
8.3 Nursing Mothers A small amount of pravastatin is excreted in human breast milk. Because of the potential for serious adverse reactions in nursing infants, women taking PRAVACHOL should not nurse [see Contraindications (4.4) ]. Pravastatin crosses the placenta and is found in fetal tissue at 30% maternal plasma levels following a single 20 mg/kg dose given to pregnant rats on gestation day 18. Similar studies in lactating rats indicate secretion of pravastatin into breast milk at 0.2 to 6.5 times higher levels than maternal plasma at exposures equivalent to 2 times human exposure at the MRHD.

Pravachol | Pravastatin Sodium Tablet Breastfeeding Analsys


Pravastatin sodium while Breastfeeding

Unsafe

CAS Number: 81093-37-0

Statin drugs do its action by inhibiting cholesterol synthesis. On latest update relevant data on breastfeeding was not found. Its high plasma protein binding makes excretion into breast milk unlikely. Ability to alter fat composition of breast milk is unknown which is important since infants are in need of high cholesterol intake for adequate brain development, cell membrane building and hormone and vitamin synthesis. Avoid taking it at least while exclusive breastfeeding. Atorvastatin is possibly the safest statin drug because a higher molecular weight that lowers excretion into breast milk even more extensively. For Pravastatin a minimal excretion has been reported. Simvastatin has a lowest oral bioavailability. Avoiding drug treatment for cholesterol as long as breastfeeding is desired would probably not harm long term result of disease. Continuing with a low fat containing diet is recommended.


Pravachol | Pravastatin Sodium Tablet Breastfeeding Analsys - 2


Pravastatin sodium while Breastfeeding

CAS Number: 81093-37-0

Pravachol | Pravastatin Sodium Tablet and breastfeeding

Levels of pravastatin in milk are low, but no relevant published information exists with its use during breastfeeding. The consensus opinion is that women taking a statin should not breastfeed because of a concern with disruption of infant lipid metabolism. However, others have argued that children homozygous for familial hypercholesterolemia are treated with statins beginning at 1 year of age, that statins have low oral bioavailability, and risks to the breastfed infant are low, especially with rosuvastatin and pravastatin.[1] Until more data become available, an alternate drug may be preferred, especially while nursing a newborn or preterm infant.


Pravachol | Pravastatin Sodium Tablet safe for breastfeeding

I am nursing mother and I have already used Pravachol | Pravastatin Sodium Tablet, what should I do?

If you observer abnormal behavior or any other health issue in infant then you should immediately call 911 or contact other contact other emergency service provider in your area otherwise closely monitor the baby and inform your doctor about your Pravachol | Pravastatin Sodium Tablet usage and time interval of breastfeeding.


I am nursing mother and my doctor has suggested me to use Pravachol | Pravastatin Sodium Tablet, is it safe?

If your doctor knows that you are breastfeeding mother and still prescribes Pravachol | Pravastatin Sodium Tablet then there must be good reason for that as Pravachol | Pravastatin Sodium Tablet is considered unsafe, It usually happens when doctor finds that overall advantage of taking outweighs the overall risk.


If I am using Pravachol | Pravastatin Sodium Tablet, will my baby need extra monitoring?

Yes, Extra monitoring is required if mother is using Pravachol | Pravastatin Sodium Tablet and breastfeeding as it is considered unsafe for baby.


Who can I talk to if I have questions about usage of Pravachol | Pravastatin Sodium Tablet in breastfeeding?

US
National Womens Health and Breastfeeding Helpline: 800-994-9662 (TDD 888-220-5446) 9 a.m. and 6 p.m. ET, Monday through Friday

UK
National Breastfeeding Helpline: 0300-100-0212 9.30am to 9.30pm, daily
Association of Breastfeeding Mothers: 0300-330-5453
La Leche League: 0345-120-2918
The Breastfeeding Network supporter line in Bengali and Sylheti: 0300-456-2421
National Childbirth Trust (NCT): 0300-330-0700

Australia
National Breastfeeding Helpline: 1800-686-268 24 hours a day, 7 days a week

Canada
Telehealth Ontario for breastfeeding: 1-866-797-0000 24 hours a day, 7 days a week